William H Sharfman MD
Hematologic Oncology, Melanoma
Associate professor of oncology and dermatology at the Johns Hopkins University School of Medicine Director of cutaneous oncology and clinical co-director for oncology at the Johns Hopkins Melanoma Program.
Join to View Full Profile
10803 Falls RoadPavilion III STE 1500Lutherville, MD 21093
Phone+1 410-583-2970
Fax+1 410-583-2980
Dr. Sharfman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 1986 - 1989- Cleveland Clinic FoundationResidency, Internal Medicine, 1982 - 1985
The University of Toledo College of MedicineClass of 1982
Certifications & Licensure
DE State Medical License Current
MD State Medical License 1989 - 2027
FL State Medical License 2020 - 2022
PA State Medical License 2020 - 2022
OH State Medical License 1985 - 1990
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- Pyrazoloacridine in Treating Patients With Metastatic Skin or Eye Melanoma Start of enrollment: 1999 Feb 01
- Melanoma Biomarker Study Start of enrollment: 2006 May 01
- PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy Start of enrollment: 2011 Aug 01
Publications & Presentations
PubMed
- 10 citationsNivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II...Shailender Bhatia, Suzanne L Topalian, William Sharfman, Tim Meyer, Neil Steven
Journal of Clinical Oncology. 2025-03-20 - 19 citationsImmune-related encephalitis after immune checkpoint inhibitor therapy.Monica W Buckley, Aanika Balaji Warner, Julie Brahmer, Laura C Cappelli, William H Sharfman
The Oncologist. 2025-01-17 - 34 citationsNivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.Ana Oaknin, Kathleen Moore, Tim Meyer, José López-Picazo González, Lot A Devriese
The Lancet. Oncology. 2024-05-01
Journal Articles
- From Validity to Clinical Utility: The Influence of Circulating Tumor DNA on Melanoma Patient Management in a Real‐World SettingKaren B Bleich, William H Sharfman, Steven P Rowe, Evan J Lipson, Megan D Schollenberger, Molecular Oncology
Press Mentions
Tip Sheet: Johns Hopkins Kimmel Cancer Center Researchers to Present at Asco Annual MeetingMay 26th, 2023
Miller-Coulson Academy Induction Set for April 17March 8th, 2017
Melanoma: Immunotherapy-Induced Vitiligo Documented as Linked to Better OutcomesMay 25th, 2015
Professional Memberships
- Fellow
- Member
- Member
- Member
- Member
External Links
- Johns Hopkins Physicianshttp://www.hopkinsmedicine.org/william-sharfman
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
